Lysoglycerophospholipids　(Lyso-GPLs)　are　an　essential　class　of　signaling　lipids　with　potential　roles　in　human　diseases,　such　as　cancer,　central　nervous　system　diseases,　and　atherosclerosis.　Current　methods　for　the　quantification　of　Lyso-GPLs　involve　complex　sample　pretreatment,　long　analysis　times,　and　insufficient　validation,　which　hinder　the　research　of　Lyso-GPLs　in　human　studies,　especially　for　Lyso-GPLs　with　low　abundance　in　human　plasma　such　as　lysophosphatidic　acid　(LPA),　lysophosphatidylinositol　(LPI),　lysophosphatidylglycerol　(LPG),　lysophosphatidylserine　(LysoPS),　lyso-platelet-activating　factor　(LysoPAF),　and　cyclic　phosphatidic　acid　(cPA).　Herein,　we　report　the　development　and　validation　of　a　simple　and　rapid　liquid　chromatography-tandem　mass　spectrometry　(LC-MS/MS)　method　for　the　quantification　of　Lyso-GPLs　with　low　abundance　in　plasma.　Protein　precipitation　using　MeOH　for　Lyso-GPL　extraction,　quick　separation　(within　18　min)　based　on　hydrophilic　interaction　liquid　chromatography　(HILIC),　and　sensitive　MS　detection　under　dynamic　multiple　reaction　monitoring　(dMRM)　mode　enabled　efficient　quantification　of　22　Lyso-GPLs　including　2　cPA,　4　LPG,　11　LPA,　2　LysoPS,　and　3　LysoPAF　in　50　mu　L　of　human　plasma.　The　present　method　showed　good　linearity　(goodness　of　fit,　0.99823-0.99995),　sensitivity　(lower　limit　of　quantification,　0.03-14.06　ng/mL),　accuracy　(73-117%),　precision　(coefficient　of　variation　＜=　28%),　carryover　(＜=　17%),　recovery　(80-110%),　and　stability　(83-123%).　We　applied　the　method　in　an　epidemiological　study　and　report　concentrations　of　18　Lyso-GPLs　in　567　human　plasma　samples　comparable　to　those　of　previous　studies.　Significant　negative　associations　of　LysoPAF　C18,　LysoPAF　C18:1,　and　LysoPAF　C16　with　homeostatic　model　assessment　for　insulin　resistance　(HOMA-IR)　level　were　observed;　this　indicates　possible　roles　of　LysoPAF　in　glucose　homeostasis.　The　application　of　the　present　method　will　improve　understanding　of　the　roles　of　circulating　low-abundant　Lyso-GPLs　in　health　and　diseases.